Kardigan is a heart health company dedicated to transforming cardiovascular medicine with a focus on making cardiovascular diseases preventable and curable. The company aims to develop multiple targeted treatments simultaneously, leveraging a cutting-edge discovery and translational research platform. This platform utilizes proprietary cardiac-specific tools to gain insights into the mechanisms of their therapeutic candidates and the individualized responses of patients. By matching critical disease drivers with appropriate treatment responders, Kardigan seeks to streamline clinical trials and deliver novel therapies to those most likely to benefit, thereby moving beyond mere symptom management toward functional cures.

The leadership team at Kardigan is composed of experienced professionals with a strong background in cardiovascular drug development, including co-founders who previously led MyoKardia to significant success. The company has raised $300 million in Series A funding to support its mission and has established strategic partnerships to enhance its capabilities. Kardigan's approach emphasizes the importance of data sharing across its programs to improve efficiency and success rates in clinical trials. With a robust portfolio of late-stage clinical candidates, Kardigan is committed to addressing unmet needs in cardiology, particularly for patients with conditions that are resistant to current therapies.

United States

Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve.

Kardigan

Company Details